Mainz Biomed NV has launched the eAArly DETECT 2 feasibility study, aimed at validating previous results on advanced adenomas using a large population of approximately 2,000 average risk patients.
Biomed Industries, Inc. Presents Breakthrough Phase 2 Results of NA-931, a First-in-Class Oral Quadruple Agonist for the Treatment of Obesity , at ADA 2025 NA-931's Phase 2 results highlight its ...
Mainz Biomed N.V., a molecular genetics diagnostic company focused on early cancer detection, reported significant milestones for the first half of 2025, including the launch of the eAArly DETECT 2 US ...
NA-831 is the only drug to date that has halted Alzheimer’s disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback